SEC Filing Summary for ARS Pharmaceuticals, Inc.

This filing details a Form 4 for ARS Pharmaceuticals, Inc. (SPRY), reporting a transaction by director Phillip M. Schneider on June 24, 2026. The transaction involved the acquisition of 30,000 stock options with a purchase price of $0.00, exercisable at $10.54 per share. These options are set to vest in full on the earlier of June 24, 2027, or the date of the Issuer's 2027 annual meeting of stockholders. The options expire on June 23, 2036. The reporting owner, Phillip M. Schneider, holds these options indirectly. This filing is classified as an OFFICER_DIRECTOR_CHANGE due to the reporting of a transaction by a director. The importance is assessed as MEDIUM due to the nature of stock options being granted.